Evercore ISI Cuts Repligen (NASDAQ:RGEN) Price Target to $130.00

Repligen (NASDAQ:RGEN) had its target price reduced by Evercore ISI from $140.00 to $130.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have an in-line rating on the biotechnology company’s stock.

Several other brokerages have also issued reports on RGEN. Wall Street Zen lowered shares of Repligen from a “buy” rating to a “hold” rating in a report on Sunday, June 29th. HC Wainwright reissued a “buy” rating and issued a $180.00 price target on shares of Repligen in a report on Monday, May 5th. Barclays started coverage on shares of Repligen in a report on Tuesday, June 24th. They issued an “overweight” rating and a $150.00 price target for the company. JPMorgan Chase & Co. decreased their price target on shares of Repligen from $200.00 to $190.00 and set an “overweight” rating for the company in a report on Tuesday, April 29th. Finally, Royal Bank Of Canada decreased their price target on shares of Repligen from $202.00 to $189.00 and set an “outperform” rating for the company in a report on Wednesday, April 30th. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and an average target price of $170.75.

Repligen Price Performance

RGEN opened at $134.00 on Tuesday. The company has a fifty day moving average price of $125.88 and a two-hundred day moving average price of $139.50. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. Repligen has a 52 week low of $102.97 and a 52 week high of $182.52. The firm has a market capitalization of $7.53 billion, a PE ratio of -297.78, a P/E/G ratio of 3.72 and a beta of 1.11.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping analysts’ consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The firm had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. During the same quarter in the previous year, the business earned $0.28 EPS. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. As a group, analysts anticipate that Repligen will post 1.72 earnings per share for the current year.

Institutional Investors Weigh In On Repligen

Institutional investors have recently added to or reduced their stakes in the stock. Signaturefd LLC lifted its position in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 124 shares in the last quarter. Sava Infond d.o.o. bought a new stake in Repligen during the 4th quarter worth about $29,000. Raiffeisen Bank International AG bought a new stake in Repligen during the 4th quarter worth about $29,000. Twin Tree Management LP bought a new stake in Repligen during the 1st quarter worth about $29,000. Finally, Itau Unibanco Holding S.A. bought a new stake in Repligen during the 4th quarter worth about $40,000. 97.64% of the stock is owned by institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.